Drug Trial Radar · NCT04658472
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Apr 28, 2021
Primary completion
Oct 1, 2025
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- Bioverativ, a Sanofi companySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: * Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive * Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary Objectives: * Part A: * Safety and tolerability of SAR445088 in CIDP * Immunogenicity of SAR445088 * Efficacy of SAR445088 with overlapping SOC (SOC-Treated group) * Part B: * Durability of efficacy during long-term treatment with SAR445088 in CIDP * Long-term immunogenicity of SAR445088 in CIDP
Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
SAR445088 (IV)Drug
Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
SAR445088 (SC)Drug
Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Standard of Care-Treated Only: Percentage of Participants With Relapse After Withdrawal of Standard of Care During the Riliprubart Treatment PeriodTime frame: From Day 1 up to Week 24
- Part A: Standard of Care-Refractory Only: Percentage of Participants With Response During the Riliprubart Treatment PeriodTime frame: From Day 1 up to Week 24
- Part A: Standard of Care-Naïve Only: Percentage of Participants With Response During the Riliprubart Treatment PeriodTime frame: From Day 1 up to Week 24
- Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)Time frame: From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks
Locations
28 sites in 10 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center- Site Number : 8400004
Los Angeles, California
University of California Irvine - Manchester Pavilion- Site Number : 8400002
Orange, California
University of Kansas Clinical Research Center- Site Number : 8400003
Fairway, Kansas
M Health Fairview University of Minnesota Medical Center - East Bank- Site Number : 8400006
Minneapolis, Minnesota
Columbia University Irving Medical Center- Site Number : 8400005
New York, New York
Investigational Site Number : 1240001
Gatineau, Quebec, Canada
Investigational Site Number : 1240002
Québec, Quebec, Canada
Investigational Site Number : 1560002
Fuzhou, China
Investigational Site Number : 1560001
Shanghai, China
Investigational Site Number : 1560004
Wuhan, China
Investigational Site Number : 2500003
Bordeaux, France
Investigational Site Number : 2500005
Le Kremlin-Bicêtre, France
Investigational Site Number : 2500001
Marseille, France
Investigational Site Number : 2500002
Nice, France
Investigational Site Number : 2760001
Düsseldorf, Germany
Investigational Site Number : 2760002
Göttingen, Germany
Investigational Site Number : 2760004
Tübingen, Germany
Investigational Site Number : 3800003
Genoa, Genova, Italy
Investigational Site Number : 3800001
Milan, Milano, Italy
Investigational Site Number : 3800005
Rozzano, Milano, Italy
Investigational Site Number : 3800002
Rome, Roma, Italy
Investigational Site Number : 5280001
Amsterdam, Netherlands
Investigational Site Number : 6160001
Lublin, Lublin Voivodeship, Poland
Investigational Site Number : 6880001
Belgrade, Serbia
Investigational Site Number : 6880003
Niš, Serbia
Investigational Site Number : 7240003
Valencia, Spain
Investigational Site Number : 7240002
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240001
Barcelona, Catalunya [Cataluña], Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.